Efficacy of tepotinib

Tepotinib is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have mutations that cause mesenchymal-to-epithelial transition (MET) exon 14 skipping. MET proteins belong to a family of enzymes called receptor tyrosine kinases, which are involved in cell growth. In NSCLC patients with "METex14 skipping," an abnormal form of the MET protein is produced, causing cancer cells to divide and grow in an uncontrolled manner.

In a major study involving 138 patients, tepotinib was effective in adult patients with non-small cell lung cancer with METex14 skipping mutations whose disease had progressed after prior treatment with other cancer drugs. Tepotinib was not compared with any other treatment or placebo (dummy treatment). About 44% (61 of 138 patients) showed partial or complete cancer shrinkage after treatment with tepotinib, and on average, response lasted more than 11 months.

The original drug of Tepotinib is a new type of drug that is not yet on the market in China and therefore has not been included in the medical insurance. The price of Tepotinib original drug specifications225mg*30 tablets per box listed overseas is around RMB 80,000 (the price may fluctuate due to the exchange rate). It has been on the market for a short time and is expensive. There are also Tepotinib generic drugs produced in other countries. The price of 225mg*60 tablets produced by a Lao pharmaceutical factory is around RMB 8,600 per box (the price may fluctuate due to the exchange rate). The ingredients of generic drugs produced abroad are basically the same as those of the original drug. For specific prices and drug details, please consult Yaode Medical Consultant.